Tykerb lapatinib regulatory update

FDA approved GSK's Tykerb lapatinib in combination with Xeloda capecitabine to treat advanced or metastatic HER2-positive breast cancer in patients

Read the full 205 word article

How to gain access

Continue reading with a
two-week free trial.